Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid–a typical case report and literature review
Frontiers in Cellular and Infection Microbiology · 16.10.2023 · 13
DOI: 10.3389/fcimb.2023.1258561 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 16.10.2023. Verfasst von Junhong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Guangzhou Chest Hospital, Guangzhou, China. Hauptthemen laut MEDLINE: Tuberculosis, Hematopoietic Stem Cell Transplantation, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tuberculosis (TB) is a rare but potentially devastating complication in hematopoietic stem cell transplantation (HSCT) recipients. Myelosuppression-related antibiotics should be used cautiously in patients with hematological malignancies, especially those undergoing bone marrow transplantation and receiving bone marrow suppression therapy. Although linezolid has become the recommended drug for severe TB, its hematological toxicity is still an obstacle to its clinical application. Contezolid is a new representative of oxazolidinones in clinical development, showing superior anti-infection efficacy, but there have been no reports on the treatment of post-HSCT TB. Case presentation We reported a patient with acute lymphoblastic leukemia suffered from pulmonary TB infection after HSCT. During anti-TB treatment, the patient had a poor response to linezolid-containing regimen, and developed side effects such as gingival bleeding and thrombocytopenia, so the administration was switched to contezolid. After 15 days of continuous treatment, the patient’s platelet increased to 58×10 9 /L, and he was discharged in stable condition. During subsequent anti-TB treatment with contezolid for more than 7 months, the platelets remained stable, and no hematological adverse reactions and no symptoms of peripheral neuropathy were observed. Moreover, repeat imaging showed that the bilateral lung lesions were significantly reduced, indicating a good outcome for the patient.
Conclusion
This was the first successful case of post-HSCT TB patients treated with contezolid-containing antibiotic management strategies, which exhibited remarkable efficacy and good safety in this deadly disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Guangzhou Chest Hospital, Guangzhou, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Li, J., Yu, Z., Jiang, Y., Lao, S., & Li, D. (2023). Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid–a typical case report and literature review. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1258561
Vancouver
Li J, Yu Z, Jiang Y, Lao S, Li D. Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid–a typical case report and literature review. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1258561
BibTeX
@article{Li2023,
author = {Li, Junhong and Yu, Zhaoxian and Jiang, Yingyi and Lao, Suihua and Li, Dexian},
title = {Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid–a typical case report and literature review},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1258561}
}
EUVIMED